Related Experiment Videos

Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy

M T Carpenter1, S G West, S A Vogelgesang

  • 1Department of Medicine, Fitzsimons Army Medical Center, Aurora, Colo. 80045-5000, USA.

Orthopedics
|March 1, 1996
PubMed

Insights

Temporarily stopping low-dose methotrexate (MTX) before joint replacement surgery may reduce infection risks for rheumatoid arthritis patients. Continuing MTX perioperatively was linked to higher rates of postoperative complications, including infections.

Area of Science:

  • Orthopedics
  • Rheumatology
  • Infectious Disease

Background:

  • Rheumatoid arthritis (RA) patients often require joint arthroplasty.
  • Methotrexate (MTX) is a common disease-modifying antirheumatic drug (DMARD) used in RA management.
  • The impact of perioperative MTX on surgical site infections (SSIs) in arthroplasty is not fully elucidated.

Purpose of the Study:

  • To investigate the effect of continuing or discontinuing low-dose methotrexate (MTX) on postoperative complications in rheumatoid arthritis patients undergoing elective total joint arthroplasty.

Main Methods:

  • Prospective observational study of 32 RA patients undergoing elective total joint arthroplasty.
  • Group 1 (n=19): Discontinued MTX the week before and during surgery.
  • Group 2 (n=13): Continued MTX throughout the perioperative period.

Main Results:

  • No postoperative infections occurred in Group 1 (19 patients, 26 procedures).
  • Four postoperative infections (2 infected prostheses, 1 infected joint fusion, 1 deep wound infection) occurred in Group 2 (13 patients, 16 procedures) (P = .03).
  • No patient experienced a postoperative rheumatoid arthritis flare in either group.

Conclusions:

  • Temporary discontinuation of MTX prior to joint arthroplasty appears to decrease the risk of postoperative infection.
  • Continuing MTX perioperatively may increase the risk of surgical site infections in RA patients undergoing arthroplasty.
  • Further research is warranted to optimize perioperative DMARD management in RA patients undergoing major orthopedic surgery.

Related Concept Videos